Answers are grounded in this paper and cite their sources.
On January 25, the FDA approved liraglutide, a glucagon-like-peptide-1 receptor agonist that can improve glycemic control in adults with type 2 diabetes. Drs. Mary Parks and Curtis Rosebraugh discuss the benefits and potentially serious safety concerns associated with this new therapy.
No takes yet. Share an insight, caveat, or question.
Parks et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: